Accéder au contenu
Merck

Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis.

Dermatology online journal (2013-10-22)
Emily Hix, Cheryl J Gustafson, Jenna L O'Neill, Karen Huang, Laura F Sandoval, Jessica Harrison, Adele Clark, Stephen R Feldman
RÉSUMÉ

Adherence in the treatment of chronic inflammatory skin diseases such as atopic dermatitis is poor. Methods to improve adherence have proven difficult. To determine whether a short course of treatment with a high-potency corticosteroid will improve adherence compared to longer treatment studies and if improvement in disease and itch continues after treatment. 10 patients with mild to moderate atopic dermatitis were instructed to apply fluocinonide 0.1% cream twice daily for 5 days. Adherence was self-reported and electronically monitored. Treatment outcomes were assessed in terms of Visual Analog Scale of Itch (VAS), Eczema Area and Severity Index (EASI), and Investigator Global Assessment (IGA) scores. The median adherence rate was 40% (range of 0-100). The median percent change in VAS from baseline measures on days 7 and 14 were 90% (range -13, 100, p=0.02) and 52% (range 0, 100, p=0.004). On days 7 and 14, 20% and 70% patients achieved an EASI-75 and 40% and 60% an IGA of 0 or 1. Small sample size limited subgroup analyses. Adherence rates with short-term treatment were similar to previously reported rates in longer term treatment studies. However, even non-adherent patients had significant improvement in itch and disease severity.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Fluocinonide, ≥98% (HPLC)